Management of Cancer in the Older Adult

Clinics in Geriatric Medicine

Volumn 28, Issue 1, 2012, Pages 33-49

  Kilari, Deepak ^a   Mohile, Supriya Gupta ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Biology of cancer; Cancer management; Elderly; Physiologic changes in the elderly, management

Indexed keywords

BEVACIZUMAB; CABAZITAXEL; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; INTERLEUKIN 2; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; SIPULEUCEL T; SUNITINIB; VASCULOTROPIN INHIBITOR;

ACNE; AGING; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; BLADDER CANCER; BLOOD PRESSURE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; COLON CANCER; COLORECTAL CANCER; COMPREHENSIVE GERIATRIC ASSESSMENT; DERMATITIS; DIARRHEA; ECTOPIA CORDIS; ESOPHAGUS CANCER; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; GERIATRIC CARE; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUROTOXICITY; OTOTOXICITY; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PROSTATE CANCER; PROTEINURIA; RASH; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; STOMACH CANCER; THROMBOEMBOLISM; THYROID CANCER; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASOSPASM; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; DECISION MAKING; DISEASE MANAGEMENT; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; NEOPLASMS; PATIENT CARE PLANNING;

EID: 84856802493     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2011.10.003     Document Type: Review

References (87)

1. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341(27):2061-2067.
2. Lang K.J., Lidder S. Under-representation of the elderly in cancer clinical trials. Br J Hosp Med (Lond) 2010, 71(12):678-681.
3. Trimble E.L., Carter C.L., Cain D., et al. Representation of older patients in cancer treatment trials. Cancer 1994, 74(7 Suppl):2208-2214.
4. Husain L.S., Collins K., Reed M., et al. Choices in cancer treatment: a qualitative study of the older women's (>70 years) perspective. Psychooncology 2008, 17(4):410-416.
5. Dix D., Cohen P. On the role of aging in carcinogenesis. Anticancer Res 1999, 19(1B):723-726.
6. Teramoto S., Fukuchi Y., Uejima Y., et al. Influences of chronic tobacco smoke inhalation on aging and oxidant-antioxidant balance in the senescence-accelerated mouse (SAM)-P/2. Exp Gerontol 1993, 28(1):87-95.
7. Bohr V.A. Human premature aging syndromes and genomic instability. Mech Ageing Dev 2002, 123(8):987-993.
8. Epstein C.J., Martin G.M., Schultz A.L., et al. Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 1966, 45(3):177-221.
9. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767.
10. Ionov Y., Peinado M.A., Malkhosyan S., et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363(6429):558-561.
11. Matheu A., Maraver A., Klatt P., et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007, 448(7151):375-379.
12. McCullough K.D., Coleman W.B., Smith G.J., et al. Age-dependent regulation of the tumorigenic potential of neoplastically transformed rat liver epithelial cells by the liver microenvironment. Cancer Res 1994, 54(14):3668-3671.
13. Markowitz S., Wang J., Myeroff L., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268(5215):1336-1338.
14. Boyd C.M., Darer J., Boult C., et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005, 294(6):716-724.
15. Koroukian S.M., Murray P., Madigan E., et al. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 2006, 24(15):2304-2310.
16. Bouchardy C., Rapiti E., Fioretta G., et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol Oct 1 2003, 21(19):3580-3587.
17. Lenihan D.J., Alencar A.J., Yang D., et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004, 104(3):655-658.
18. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5(3):224-237.
19. McLean A.J., Le Couteur D.G. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004, 56(2):163-184.
20. Girinsky T., Cosset J.M. Pulmonary and cardiac late effects of ionizing radiations alone or combined with chemotherapy. Cancer Radiother 1997, 1(6):735-743. [in French].
21. Dees E.C., O'Reilly S., Goodman S.N., et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000, 18(6):521-529.
22. Brunello A., Sandri R., Extermann M. Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool. Cancer Treat Rev 2009, 35(6):487-492.
23. Reuben D.B., Rubenstein L.V., Hirsch S.H., et al. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 1992, 93(6):663-669. [erratum in Am J Med 199;94(5):560; Am J Med 1993;94(2):232].
24. Newman A.B., Yanez D., Harris T., et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001, 49(10):1309-1318.
25. Seeman T.E., Berkman L.F., Kohout F., et al. Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol 1993, 3(4):325-335.
26. Extermann M., Meyer J., McGinnis M., et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004, 49(1):69-75.
27. Hurria A., Togawa K., Mohile S.G., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29(25):3457-3465.
28. Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007, 25(14):1824-1831.
29. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2(9):533-543.
30. Gridelli C., Maione P., Rossi A., et al. Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer 2009, 66(3):282-286.
31. Fry W.A., Phillips J.L., Menck H.R. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999, 86(9):1867-1876.
32. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94(3):173-181.
33. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311(7010):899-909. Anonymous.
34. Lilenbaum R.C., Herndon J.E., List M.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23(1):190-196.
35. Quoix E., Zalcman G.R., Oster J.P., et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378(9796):1079-1088.
36. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
37. Owonikoko T.K., Ragin C.C., Belani C.P., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007, 25(35):5570-5577.
38. Larive S., Bombaron P., Riou R., et al. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer 2002, 35(1):1-7.
39. Horner M., Ries L., Krapcho M. SEER cancer statistics review, 1975-2006 2009, National Cancer Institute, Bethesda (MD).
40. Anderson J., Van Poppel H., Bellmunt J., et al. Chemotherapy for older patients with prostate cancer. BJU Int 2007, 99(2):269-273.
41. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26(2):242-245.
42. Beer T.M., Berry W., Wersinger E.M., et al. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003, 2(3):167-172.
43. Fossa S.D. A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer. Front Radiat Ther Oncol 2008, 41:108-116.
44. Italiano A., Ortholan C., Oudard S., et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009, 55(6):1368-1375.
45. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364(21):1995-2005.
46. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
47. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376(9747):1147-1154.
48. Messing E. Urothelial tumors of the bladder. Campbell-Walsh urology 2007, 2407-2446. Saunders Elsevier, Philadelphia. 9th edition. M.F. Campbell, A.J. Wein, L.R. Kavoussi (Eds.).
49. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
50. Schultzel M., Saltzstein S.L., Downs T.M., et al. Late age (85 years or older) peak incidence of bladder cancer. J Urol 2008, 179(4):1302-1306.
51. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19(3):666-675.
52. Prout G.R., Wesley M.N., Yancik R., et al. Age and comorbidity impact surgical therapy in older bladder carcinoma patients. Cancer 2005, 104(8):1638-1647.
53. Resorlu B., Beduk Y., Baltaci S., et al. The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy. BJU Int 2009, 103(4):480-483.
54. Vaughn D.J., Manola J., Dreicer R., et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896). Cancer 2002, 95(5):1022-1027.
55. Linardou H., Aravantinos G., Efstathiou E., et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 2004, 64(3):479-484.
56. Murai M. Editorial comment on: impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 2008, 54(1):140-141.
57. Pantuck A.J., Zisman A., Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 2001, 166(5):1611-1623.
58. Nguyen M.M., Gill I.S., Ellison L.M., et al. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol 2006, 176(6 Pt 1):2397-2400. [discussion: 2400].
59. Kader A.K., Tamboli P., Luongo T., et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol 2007, 177(3):855-861.
60. Vogelzang N.J. Another step toward the cure of metastatic renal cell carcinoma?. J Clin Oncol 2010, 28(34):5017-5019.
61. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134.
62. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124.
63. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281.
64. Rini B.I., Jaeger E., Weinberg V., et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006, 98(4):756-762.
65. Kohne C.H., Folprecht G., Goldberg R.M., et al. Chemotherapy in elderly patients with colorectal cancer. Oncologist 2008, 13(4):390-402.
66. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230(3):309-318. [discussion: 318-31].
67. Figueras J., Ramos E., Lopez-Ben S., et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile?. Clin Transl Oncol 2007, 9(6):392-400.
68. Adam R., Frilling A., Elias D., et al. Liver resection of colorectal metastases in elderly patients. Br J Surg 2010, 97(3):366-376.
69. Folprecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004, 15(9):1330-1338.
70. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370(9582):135-142.
71. Figer A., Perez-Staub N., Carola E., et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007, 110(12):2666-2671.
72. Chiara S., Nobile M.T., Vincenti M., et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998, 42(4):336-340.
73. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24(25):4085-4091. [erratum in J Clin Oncol 2008;26(17):2925-6].
74. Cassidy J., Saltz L.B., Giantonio B.J., et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010, 136(5):737-743.
75. Li D., Xie K., Wolff R., et al. Pancreatic cancer. Lancet 2004, 363(9414):1049-1057.
76. Cooperman A.M. Pancreatic cancer: the bigger picture. Surg Clin North Am 2001, 81(3):557-574.
77. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
78. Locher C., Fabre-Guillevin E., Brunetti F., et al. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol 2008, 68(2):178-182.
79. Marechal R., Demols A., Gay F., et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008, 36(3):e16-e21.
80. Katakura Y., Nakahara K., Kobayashi M., et al. Gemcitabine therapy for unresectable pancreatic cancer in elderly patients. Nippon Shokakibyo Gakkai Zasshi 2010, 107(3):396-406. [in Japanese].
81. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825.
82. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
83. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
84. Trumper M., Ross P.J., Cunningham D., et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 2006, 42(7):827-834.
85. Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994, 5(7):609-616. 1994.
86. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24(31):4991-4997.
87. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46.